In December of last year, the Centers for Medicare and Medicaid Services (CMS) published their Final Decision regarding outpatient intravenous insulin therapy.  They decided there was not sufficient evidence that the therapy improves health outcomes in Medicare beneficiaries and they made a national decision not to pay for this class of therapy.   

Thus, Medicare will not pay for MAT® treatment or any other outpatient IV insulin treatment.   In their discussion, it was clear that Medicare will not pay for such a therapy unless very large clinical trials demonstrate benefits in patients with type 2 diabetes.